PDE5A and Schnyder corneal dystrophy: In uncontrolled clinical studies involving men with SCD, PDE5 inhibitor therapy administered by continuous, long-term dosing unassociated with sexual stimulation proved efficacious in reducing priapism-related events [12], [13].